Dipharma Francis (“Dipharma”), a global CDMO and a leading manufacturer of APIs and intermediates for generic and contract manufacturing markets, is pleased to announce that Kalexsyn, Inc., a Michigan corporation (“Kalexsyn”) acquired in 2018, has been merged into its 100% owner, Dipharma Inc., a Delaware corporation and member of the Dipharma Group, effective January 01, 2022.
The merger represents the last step of Kalexsyn’s integration into the Dipharma Group. That process started on May 17th, 2018 with the acquisition of the Company, in accordance with Dipharma’s strategic decision to strengthen its position in the CDMO market and leverage its presence in the United States.
“We have been working hard on combining Kalexsyn’s outstanding CRO offering with Dipharma’s strong technical competences to develop a state of the art cGMP operation in Kalamazoo which now plays an essential role in Dipharma’s global business development network,” said Jorge Nogueira, Chairman of Dipharma Inc.’s Board of Directors and CEO of Dipharma Francis. “Now, the merger completes the formal act of that successful integration, which has enabled our Company to expand the range of services we offer to our customers, both in US and worldwide, from discovery research through commercialization.”
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
